Breast cancer (Dove Medical Press) · 2025
Comprehensive Analysis and Experimental Validation of Single-Cell and Transcriptome Sequencing Reveal SGO2 as a Novel Biomarker for Breast Cancer.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Yu-Fan, Yuan Ying, Chen Cheng, Zhu Ming-Liao, Xu Shuo-Yang, Wu Shou-Qian, Gao Yuan, Meng Li-Wei
Аннотация
PURPOSE: SGO2 maintains the binding of sisters chromatids by protecting the adhesive complex at the centromere, thus ensuring the correct separation of chromosomes during mitosis and meiosis. And this study explored its role in breast cancer (BC) progression.
METHODS: SGO2 expression in breast cancer was analyzed utilizing data from TCGA, GTEX, and HPA databases. Our study leveraged clinical data to predict outcomes. Subsequently, we conducted a GSEA enrichment analysis, dove into co-expression profiling, explored immune cell infiltration patterns, examined drug sensitivity, and analyzed single-cell data. To delve deeper, we validated the functional role of SGO2 through in vitro cellular experiments.
RESULTS: Survival analysis demonstrated a notable correlation between heightened SGO2 expression and unfavorable cancer survival rates. Gene set enrichment analysis (GSEA) highlighted the participation of SGO2 in DNA replication. Immunoinfiltration analysis indicated a connection between SGO2 and several immune cell types, with single-cell analysis verifying SGO2 expression across diverse cell populations.
CONCLUSION: SGO2 may serve as a valuable prognostic biomarker and a potential therapeutic target in breast cancer.
METHODS: SGO2 expression in breast cancer was analyzed utilizing data from TCGA, GTEX, and HPA databases. Our study leveraged clinical data to predict outcomes. Subsequently, we conducted a GSEA enrichment analysis, dove into co-expression profiling, explored immune cell infiltration patterns, examined drug sensitivity, and analyzed single-cell data. To delve deeper, we validated the functional role of SGO2 through in vitro cellular experiments.
RESULTS: Survival analysis demonstrated a notable correlation between heightened SGO2 expression and unfavorable cancer survival rates. Gene set enrichment analysis (GSEA) highlighted the participation of SGO2 in DNA replication. Immunoinfiltration analysis indicated a connection between SGO2 and several immune cell types, with single-cell analysis verifying SGO2 expression across diverse cell populations.
CONCLUSION: SGO2 may serve as a valuable prognostic biomarker and a potential therapeutic target in breast cancer.